HUTCHMED (China) Limited (HCM)
NASDAQ: HCM · Real-Time Price · USD
13.78
-0.07 (-0.51%)
At close: Mar 9, 2026, 4:00 PM EDT
13.77
-0.01 (-0.07%)
After-hours: Mar 9, 2026, 4:10 PM EDT
HUTCHMED (China) Revenue
In the year 2025, HUTCHMED (China) had annual revenue of $548.51M, down -12.96%. HUTCHMED (China) had revenue of $270.84M in the half year ending December 31, 2025, a decrease of -11.24%.
Revenue (ttm)
$548.51M
Revenue Growth
-12.96%
P/S Ratio
4.45
Revenue / Employee
$308,153
Employees
1,780
Market Cap
2.44B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 548.51M | -81.69M | -12.96% |
| Dec 31, 2024 | 630.20M | -207.80M | -24.80% |
| Dec 31, 2023 | 838.00M | 411.59M | 96.52% |
| Dec 31, 2022 | 426.41M | 70.28M | 19.73% |
| Dec 31, 2021 | 356.13M | 128.15M | 56.21% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bausch Health Companies | 10.27B |
| Perrigo Company | 4.25B |
| Hims & Hers Health | 2.35B |
| Phibro Animal Health | 1.46B |
| Prestige Consumer Healthcare | 1.10B |
| ANI Pharmaceuticals | 883.37M |
| BioCryst Pharmaceuticals | 874.84M |
| Supernus Pharmaceuticals | 718.95M |
HCM News
- 12 hours ago - HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China - GlobeNewsWire
- 3 days ago - Intended Retirement of Independent Non-executive Director and changes of composition of board committees - GlobeNewsWire
- 4 days ago - HUTCHMED (China) Limited (HCM) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - An Overview of HUTCHMED (China)'s Earnings - Benzinga
- 4 weeks ago - HUTCHMED to Announce 2025 Final Results - GlobeNewsWire
- 5 weeks ago - HUTCHMED (China) Ltd (HCM) Stock Price Down 3.53% on Feb 2 - GuruFocus
- 7 weeks ago - HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet - GlobeNewsWire
- 2 months ago - Positive China Trial Data Moves HUTCHMED Closer To Rare Blood Disorder Drug Filing In 2026 - Benzinga